Daniel J. Lippis - Mar 7, 2024 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Role
CVP, JAPAC
Signature
Linda J. Park, Attorney-in-Fact
Stock symbol
EW
Transactions as of
Mar 7, 2024
Transactions value $
-$93,004
Form type
4
Date filed
3/7/2024, 06:22 PM
Previous filing
Feb 20, 2024
Next filing
Apr 9, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EW Common Stock Options Exercise $63K +1.72K +9.96% $36.75 18.9K Mar 7, 2024 Direct F1
transaction EW Common Stock Sale -$156K -1.72K -9.06% $90.98 17.2K Mar 7, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EW Employee Stock Option (Right to Acquire) Options Exercise $0 -1.72K -50.01% $0.00 1.71K Mar 7, 2024 Common Stock 1.72K $36.75 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2023.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.